 Eric Prince
Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Craniopharyngioma | 8 | 2025 | 74 | 3.660 |
Why?
| | Pituitary Neoplasms | 7 | 2025 | 190 | 2.810 |
Why?
| | Decision Support Systems, Clinical | 2 | 2025 | 226 | 1.450 |
Why?
| | Artificial Intelligence | 2 | 2025 | 279 | 1.450 |
Why?
| | Brain Neoplasms | 8 | 2025 | 1238 | 1.040 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2025 | 110 | 0.890 |
Why?
| | Computational Biology | 2 | 2025 | 644 | 0.770 |
Why?
| | Cellular Senescence | 1 | 2024 | 189 | 0.770 |
Why?
| | Machine Learning | 2 | 2025 | 493 | 0.760 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2020 | 89 | 0.650 |
Why?
| | Software | 1 | 2025 | 665 | 0.630 |
Why?
| | Cerebellar Neoplasms | 2 | 2020 | 152 | 0.590 |
Why?
| | Medulloblastoma | 2 | 2020 | 193 | 0.580 |
Why?
| | Epilepsy, Temporal Lobe | 1 | 2017 | 38 | 0.540 |
Why?
| | Biomarkers, Tumor | 3 | 2024 | 1276 | 0.540 |
Why?
| | Ependymoma | 4 | 2020 | 165 | 0.540 |
Why?
| | Checkpoint Kinase 1 | 1 | 2016 | 30 | 0.520 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2020 | 752 | 0.500 |
Why?
| | Glioma | 4 | 2025 | 395 | 0.490 |
Why?
| | Laser Therapy | 1 | 2017 | 130 | 0.480 |
Why?
| | Transcriptome | 1 | 2020 | 971 | 0.420 |
Why?
| | Magnetic Resonance Imaging | 2 | 2020 | 3566 | 0.350 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 2691 | 0.330 |
Why?
| | Brain | 2 | 2022 | 2668 | 0.320 |
Why?
| | Chromosomes, Human, Pair 1 | 2 | 2019 | 71 | 0.290 |
Why?
| | Genes, myc | 2 | 2020 | 48 | 0.290 |
Why?
| | Infratentorial Neoplasms | 2 | 2019 | 63 | 0.280 |
Why?
| | Sirtuin 2 | 1 | 2025 | 24 | 0.230 |
Why?
| | SMARCB1 Protein | 1 | 2025 | 31 | 0.230 |
Why?
| | Pyrazoles | 2 | 2020 | 423 | 0.230 |
Why?
| | Child | 10 | 2025 | 21935 | 0.230 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2025 | 1396 | 0.220 |
Why?
| | Cell Cycle Proteins | 2 | 2020 | 617 | 0.220 |
Why?
| | Macrophage Activation | 1 | 2025 | 201 | 0.220 |
Why?
| | Clonal Evolution | 1 | 2024 | 45 | 0.210 |
Why?
| | Rhabdoid Tumor | 1 | 2025 | 99 | 0.210 |
Why?
| | Cell Line, Tumor | 6 | 2025 | 3412 | 0.210 |
Why?
| | Phagocytosis | 1 | 2025 | 380 | 0.210 |
Why?
| | Tumor Burden | 1 | 2024 | 309 | 0.200 |
Why?
| | Humans | 21 | 2025 | 137585 | 0.190 |
Why?
| | Circle of Willis | 1 | 2022 | 7 | 0.190 |
Why?
| | MAP Kinase Signaling System | 1 | 2024 | 320 | 0.190 |
Why?
| | Preoperative Period | 1 | 2020 | 129 | 0.170 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2024 | 1079 | 0.170 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2024 | 528 | 0.170 |
Why?
| | Disease Progression | 2 | 2024 | 2757 | 0.160 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2019 | 16 | 0.160 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2020 | 80 | 0.160 |
Why?
| | Pyrimidinones | 1 | 2020 | 113 | 0.160 |
Why?
| | Cell Survival | 3 | 2017 | 1120 | 0.150 |
Why?
| | Deoxycytidine | 1 | 2020 | 179 | 0.150 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 225 | 0.140 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2019 | 215 | 0.140 |
Why?
| | Everolimus | 1 | 2017 | 91 | 0.140 |
Why?
| | Macrophages | 1 | 2025 | 1547 | 0.140 |
Why?
| | Stereotaxic Techniques | 1 | 2017 | 39 | 0.140 |
Why?
| | Antineoplastic Agents | 2 | 2020 | 2129 | 0.140 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 313 | 0.140 |
Why?
| | Morpholines | 1 | 2017 | 122 | 0.130 |
Why?
| | Brain Stem Neoplasms | 1 | 2017 | 83 | 0.130 |
Why?
| | Models, Theoretical | 1 | 2020 | 578 | 0.130 |
Why?
| | Benzodiazepinones | 1 | 2016 | 17 | 0.130 |
Why?
| | Chromosome Aberrations | 1 | 2017 | 156 | 0.130 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2020 | 434 | 0.130 |
Why?
| | Pteridines | 1 | 2016 | 20 | 0.130 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2016 | 43 | 0.130 |
Why?
| | Urea | 1 | 2016 | 81 | 0.130 |
Why?
| | Thiophenes | 1 | 2016 | 117 | 0.120 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1774 | 0.120 |
Why?
| | Phenotype | 1 | 2024 | 3196 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 437 | 0.120 |
Why?
| | Disease-Free Survival | 1 | 2016 | 686 | 0.110 |
Why?
| | Cisplatin | 1 | 2016 | 320 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 889 | 0.110 |
Why?
| | Proto-Oncogene Proteins | 1 | 2016 | 648 | 0.100 |
Why?
| | Algorithms | 1 | 2020 | 1704 | 0.100 |
Why?
| | Prognosis | 2 | 2019 | 4030 | 0.090 |
Why?
| | Apoptosis | 2 | 2019 | 2553 | 0.090 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4295 | 0.080 |
Why?
| | Male | 6 | 2024 | 67762 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1692 | 0.070 |
Why?
| | Female | 6 | 2024 | 73304 | 0.070 |
Why?
| | Mice | 4 | 2025 | 17787 | 0.060 |
Why?
| | CD47 Antigen | 1 | 2025 | 38 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2017 | 2654 | 0.060 |
Why?
| | Cell Differentiation | 2 | 2025 | 1991 | 0.050 |
Why?
| | Animals | 5 | 2025 | 36940 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2024 | 220 | 0.050 |
Why?
| | Treatment Outcome | 1 | 2017 | 10811 | 0.050 |
Why?
| | beta Catenin | 1 | 2024 | 253 | 0.050 |
Why?
| | Cell Proliferation | 2 | 2019 | 2475 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2024 | 15657 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 367 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2020 | 195 | 0.040 |
Why?
| | Middle Aged | 1 | 2020 | 33479 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 601 | 0.040 |
Why?
| | Quality of Life | 2 | 2020 | 2892 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2019 | 955 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2020 | 217 | 0.030 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2020 | 249 | 0.030 |
Why?
| | Receptors, HIV | 1 | 2017 | 24 | 0.030 |
Why?
| | Mucin-1 | 1 | 2017 | 21 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 62 | 0.030 |
Why?
| | Cytogenetic Analysis | 1 | 2017 | 33 | 0.030 |
Why?
| | Child, Preschool | 2 | 2024 | 11074 | 0.030 |
Why?
| | Microarray Analysis | 1 | 2017 | 117 | 0.030 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2017 | 194 | 0.030 |
Why?
| | Adult | 1 | 2020 | 37929 | 0.030 |
Why?
| | Ki-67 Antigen | 1 | 2017 | 112 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 125 | 0.030 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2017 | 100 | 0.030 |
Why?
| | Benzamides | 1 | 2017 | 216 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2019 | 872 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 1236 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 840 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 325 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2017 | 363 | 0.030 |
Why?
| | Prevalence | 1 | 2022 | 2734 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1972 | 0.030 |
Why?
| | Cell Cycle | 1 | 2017 | 601 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2020 | 2167 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2016 | 767 | 0.030 |
Why?
| | Pyrimidines | 1 | 2017 | 470 | 0.030 |
Why?
| | Cohort Studies | 1 | 2024 | 5742 | 0.030 |
Why?
| | DNA Damage | 1 | 2016 | 420 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 843 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 812 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2017 | 580 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 2057 | 0.030 |
Why?
| | Phosphorylation | 1 | 2017 | 1759 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2017 | 712 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5131 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2017 | 1502 | 0.020 |
Why?
| | Transcription Factors | 1 | 2017 | 1719 | 0.020 |
Why?
| | Signal Transduction | 1 | 2020 | 5079 | 0.020 |
Why?
| | Infant | 1 | 2019 | 9465 | 0.010 |
Why?
| | Adolescent | 1 | 2024 | 21513 | 0.010 |
Why?
|
|
Prince's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|